top of page

New ChemBioHub Paper

🔍 How do you assess selectivity for #covalent inhibitors? Our latest study just out in The Journal of Medicinal Chemistry reveals fascinating insights. 👇

Dual pharmacology: Covalent inhibitors can unexpectedly interact with target proteins via non-covalent interactions. In our study, we explore this phenomenon using biochemical, biophysical, and cell target engagement assays.

Case Study: The FDA-approved #BTK inhibitor #ibrutinib surprised us! It not only targets kinases but also binds and inhibits two non-kinase proteins: NUDT5 and NUDT14. 🎯

Warhead Independence: Interestingly, these effects are independent of the reactive acrylamide warhead. Mass spectrometry and protein crystallography confirm this unexpected behavior. 💡

New scaffold to explore ADP-ribose metabolism: By performing SAR studies, we identify a first-in-class, non-covalent dual inhibitor for NUDT5 and NUDT14. 🌟

Recent Posts

See All

Two open postdoc positions available!

We are looking for two enthusiastic postdoctoral fellows with expertise in structural biology to join us in our effort to study the function of proteins involved in #ubiquitination & #RNAmetabolism -

Open PostDoc position!

Great news: we have an open position for a PostDoc in structural biology/ biochemisrty. We would love to welcome you to our team, please apply here.


Congratulations to Ruth, @MonikaGullerova & team on their new paper @CellReports showing how RNA transcribed during DSB repair disrupts the interaction between TIRR (NUDT16L1) and 53BP1! Glad we could


bottom of page